# A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects

> **NCT05409326** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** TQH2722 injection
- **DRUG:** Placebo to match TQH2722

## Key facts

- **NCT ID:** NCT05409326
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06
- **Primary completion:** 2023-06
- **Final completion:** 2023-08
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2022-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05409326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05409326, "A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05409326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*